If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 61 - 70 of 279

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Objective
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
Categories
Cancer, Other Gastrointestinal, Gynecologic Cancers, Kidney, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Thoracic Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Objective
The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
Protocol No
REGENERON-R7075-ONC-2009
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Larynx, Gastrointestinal Cancers, Lip, Oral Cavity and Pharynx, Thoracic Cancers, Breast Cancers, Head and Neck Cancers, Skin Cancers